newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics Reports Third Quarter 2022 Financial Results

- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical